Table 1.
Assumptions.
Table 2.
Additional cost scenarios at launch.
Fig 1.
Reduction of new annual HIV infections with and without an AIDS vaccine under different IFE scale-up scenarios between 2010 and 2070.
Vaccine and implementation characteristics are outlined in Table 1.
Fig 2.
Reduction of new annual HIV infections with PrEP, TasP and vaccination added individually and in combination to the Full Scale-up of IFE between 2015 and 2070.
Vaccine and implementation characteristics are outlined in Table 1. Assumptions on PrEP and TasP can be found in Stover et al. 2014 [14].
Fig 3.
Reduction of new annual HIV infections under Full Scale-up of IFE according to vaccine efficacy between 2025 and 2070 (vaccine introduced in 2027).
Other vaccine and implementation characteristics are outlined in Table 1.
Table 3.
Potential new HIV infections averted in LMICs by vaccine efficacy.
Other vaccine and implementation characteristics are outlined in Table 1.
Fig 4.
Reduction of new annual HIV infections under Full Scale-up of IFE according to vaccine uptake between 2025 and 2070 (vaccine introduced in 2027).
Other vaccine and implementation characteristics are outlined in Table 1.
Table 4.
Potential new HIV infections averted in LMICs by vaccine uptake.
Fig 5.
Cost per QALY gained with an AIDS vaccine in LICs added to Full Scale-up of IFE and 50% Scale-up of IFE (discounted at 3% per year).
Vaccine and implementation characteristics (base case) are outlined in Table 1.
Fig 6.
Cost per QALY gained (2027–2070) according to vaccine efficacy under two cost scenarios in LICs (discounted at 3% per year) when a vaccine is added to Full Scale-up of IFE.
Other vaccine and implementation characteristics (base case) are outlined in Table 1. For cost assumptions see Table 2.
Fig 7.
Cost per QALY gained (2027–2070) according to vaccine coverage under two cost scenarios in LICs (discounted at 3% per year) when a vaccine is added to Full Scale-up of IFE.
Other vaccine and implementation characteristics (base case) are outlined in Table 1. For cost assumptions see Table 2.
Fig 8.
Estimated total costs for an AIDS vaccination program with base-case characteristics in LMICs under different cost-per-regimen scenarios (see Table 2).
Base-case vaccine and implementation characteristics are outlined in Table 1.
Fig 9.
Costs for both Full Scale-up of IFE as a whole and the ART component with this scale-up and number of people on antiretroviral treatment both with and without AIDS vaccination (base case-characteristics).
Base-case vaccine and implementation characteristics are outlined in Table 1. For base-case cost assumptions see Table 2.